Sobre o anarquivamento – um encadeamento a partir de Walter Benjamin

O artigo faz uma análise de uma série de obras de arte, sobretudofeitas após a Segunda Guerra Mundial, como uma tentativa de propor a figura do arquivo como uma chave para organizarmos o que se passa na nossa cultura hoje. No século XX o derretimento do arquivo central da razão ocidental serviu para desencadear um trabalho de rememoração e recoleção dos arquivos. A virada biológica entronizou a noção de herança genética e de processo de reinscrição de arquivos herdados. Já a virada cibernética generalizou discursos sobre memórias, arquivos, gravação e apagamento de informações. Os artistas, nessa paisagem, vêm pensando, desde o romantismo, contra-estratégias diante da arquivação e arquivonomia monológicas: eles se tornaram anarquivadores

Cytokine Production but Lack of Proliferation in Peripheral Blood Mononuclear Cells from Chronic Chagas' Disease Cardiomyopathy Patients in Response to T. cruzi Ribosomal P Proteins

Background:Trypanosoma cruzi ribosomal P proteins, P2β and P0, induce high levels of antibodies in patients with chronic Chagas' disease Cardiomyopathy (CCC). It is well known that these antibodies alter the beating rate of cardiomyocytes and provoke apoptosis by their interaction with β1-adrenergic and M2-muscarinic cardiac receptors. Based on these findings, we decided to study the cellular immune response to these proteins in CCC patients compared to non-infected individuals.Methodology/Principal findings:We evaluated proliferation, presence of surface activation markers and cytokine production in peripheral blood mononuclear cells (PBMC) stimulated with P2β, the C-terminal portion of P0 (CP0) proteins and T. cruzi lysate from CCC patients predominantly infected with TcVI lineage. PBMC from CCC patients cultured with P2β or CP0 proteins, failed to proliferate and express CD25 and HLA-DR on T cell populations. However, multiplex cytokine assays showed that these antigens triggered higher secretion of IL-10, TNF-α and GM-CSF by PBMC as well as both CD4+ and CD8+ T cells subsets of CCC subjects. Upon T. cruzi lysate stimulation, PBMC from CCC patients not only proliferated but also became activated within the context of Th1 response. Interestingly, T. cruzi lysate was also able to induce the secretion of GM-CSF by CD4+ or CD8+ T cells.Conclusions/Significance:Our results showed that although the lack of PBMC proliferation in CCC patients in response to ribosomal P proteins, the detection of IL-10, TNF-α and GM-CSF suggests that specific T cells could have both immunoregulatory and pro-inflammatory potential, which might modulate the immune response in Chagas' disease. Furthermore, it was possible to demonstrate for the first time that GM-CSF was produced by PBMC of CCC patients in response not only to recombinant ribosomal P proteins but also to parasite lysate, suggesting the value of this cytokine to evaluate T cells responses in T. cruzi infection.Fil: Longhi, Silvia Andrea. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica; ArgentinaFil: Atienza, Augusto. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Ramos Mejía"; ArgentinaFil: Perez Prados, Graciela. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Juan A. Fernández"; ArgentinaFil: Buying, Alcinette. Torrey Pines Institute for Molecular Studies; Estados UnidosFil: Balouz, Virginia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Instituto de Investigaciones Biotecnológicas. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas; ArgentinaFil: Buscaglia, Carlos Andres. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - La Plata. Instituto de Investigaciones Biotecnológicas. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas; ArgentinaFil: Santos, Radleigh. Torrey Pines Institute for Molecular Studies; Estados UnidosFil: Tasso, Laura Mónica. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; ArgentinaFil: Bonato, Ricardo. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Ramos Mejía"; ArgentinaFil: Chiale, Pablo. Gobierno de la Ciudad de Buenos Aires. Hospital General de Agudos "Ramos Mejía"; ArgentinaFil: Pinilla, Clemencia. Torrey Pines Institute for Molecular Studies; Estados UnidosFil: Judkowski, Valeria A.. Torrey Pines Institute for Molecular Studies; Estados UnidosFil: Gomez, Karina Andrea. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr. Héctor N. Torres"; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica; Argentin

Os efeitos dos Distúrbios Respiratórios do sono na população brasileira: uma exploração multidisciplinar da doença apneia obstrutiva do sono

Obstructive sleep apnea-hypopnea syndrome (OSAS) is a disease that mainly affects elderly and obese people, but can be present in children and adolescents, often due to hypertrophy of adenoids and palatine tonsils. Furthermore, it is important to highlight that in patients with OSAHS it is observed that the pharyngeal dilator muscles are more activated in the watch compared to control, however, with sleep, there is a reduction in neuromuscular reflexes and consequently impairment of the ability of these muscles to respond to sleep. pressure, which leaves these muscles vulnerable to collapse during sleep and results in episodes of obstructive sleep apnea. Furthermore, a narrower upper airway, genetic factors, tonsil and adenoid hypertrophy, mandibular retrognathia and variations in craniofacial structure are associated with a greater risk of developing OSAS. Regarding diagnosis, the all-night polysomnographic study is the main diagnostic method, which also allows the doctor to classify the severity of the problem. Regarding the treatment, it is highlighted that it is a comprehensive treatment that ranges from surgeries to the use of devices such as CPAP and intraoral devices.El síndrome de apnea-hipopnea obstructiva del sueño (SAOS) es una enfermedad que afecta principalmente a personas mayores y obesas, pero puede estar presente en niños y adolescentes, muchas veces debido a una hipertrofia de las adenoides y las amígdalas palatinas. Además, es importante resaltar que en pacientes con SAHOS se observa que los músculos dilatadores faríngeos están más activados en el reloj en comparación con el control, sin embargo, con el sueño hay una reducción de los reflejos neuromusculares y en consecuencia deterioro de la capacidad de estos. Los músculos responden a la presión del sueño, lo que deja a estos músculos vulnerables al colapso durante el sueño y resulta en episodios de apnea obstructiva del sueño. Además, una vía aérea superior más estrecha, factores genéticos, hipertrofia de amígdalas y adenoides, retrognatia mandibular y variaciones en la estructura craneofacial se asocian con un mayor riesgo de desarrollar SAOS. En cuanto al diagnóstico, el principal método diagnóstico es el estudio polisomnográfico nocturno, que también permite al médico clasificar la gravedad del problema. En cuanto al tratamiento, se destaca que es un tratamiento integral que abarca desde cirugías hasta el uso de dispositivos como CPAP y dispositivos intraorales.A síndrome da apneia-hipopneia obstrutiva do sono (SAHOS) é uma doença que acomete principalmente pessoas idosas e obesas, porém pode estar presente em crianças e adolescentes muitas vezes devido a hipertrofia de adenoides e das amígdalas palatinas. Ademais, é importante destacar que em pacientes com SAHOS observa-se que os músculos dilatadores da faringe estão mais ativados na vigia em relação ao controle, contudo, com o sono, há redução dos reflexos neuromusculares e consequentemente prejuízo da habilidade desses músculos em responder à pressão, o que deixa esses músculos vulneráveis para o colapso durante o sono e faz com que temos como resultado episódios de apneia obstrutiva do sono. Além disso, uma via aérea superior mais estreita, fatores genéticos, hipertrofia de amígdalas e adenoides, retrognatia mandibular e variações na estrutura craniofacial, estão associadas a um maior risco de desenvolvimento de SAOS. Sobre o diagnostico o estudo polissonográfico de noite inteira é o principal método diagnostico, sendo que esse ainda possibilita ao medico classificar a gravidade do problema. Sobre o tratamento destaca-se que é um tratamento abrangente que vai desde cirurgias até o uso de aparelhos como o CPAP e dispositivos intraorais

Caminhos para o Diagnóstico Precoce: Biomarcadores Neurogenéticos na Doença de Alzheimer.

This paper proposes a literature review on neurogenetic biomarkers in Alzheimer's disease (AD), highlighting their fundamental role in early diagnosis and understanding of the disease's pathogenesis. The analysis covers the identification of specific genetic variants, such as those in the TOMM40 gene, and polymorphisms identified through genome-wide association studies (GWAS). Additionally, the differential expression of genes associated with AD in early stages offers a unique opportunity for more effective therapeutic interventions. Despite advances, challenges such as external validation and genetic variability are crucial. The neurogenetic approach represents progress in understanding the genetic heterogeneity in AD, providing a foundation for future research. The abstract highlights the promising implications of neurogenetic biomarkers and emphasizes the importance of ethical and social awareness.Este trabalho propõe uma revisão de literatura sobre biomarcadores neurogenéticos na doença de Alzheimer (DA), destacando seu papel fundamental no diagnóstico precoce e na compreensão da patogênese da doença. A análise abrange a identificação de variantes genéticas específicas, como aquelas no gene TOMM40, e polimorfismos identificados por meio de estudos de associação genômica ampla (GWAS). Além disso, a expressão diferencial de genes associados à DA em estágios iniciais oferece uma oportunidade única para intervenções terapêuticas mais eficazes. Apesar dos avanços, desafios como a validação externa e a variabilidade genética são cruciais. A abordagem neurogenética representa um avanço na compreensão da heterogeneidade genética na DA, fornecendo uma base para pesquisas futuras. O resumo destaca as implicações promissoras dos biomarcadores neurogenéticos e destaca a importância da conscientização ética e social

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries

Abstract Background Healthcare cannot achieve net-zero carbon without addressing operating theatres. The aim of this study was to prioritize feasible interventions to reduce the environmental impact of operating theatres. Methods This study adopted a four-phase Delphi consensus co-prioritization methodology. In phase 1, a systematic review of published interventions and global consultation of perioperative healthcare professionals were used to longlist interventions. In phase 2, iterative thematic analysis consolidated comparable interventions into a shortlist. In phase 3, the shortlist was co-prioritized based on patient and clinician views on acceptability, feasibility, and safety. In phase 4, ranked lists of interventions were presented by their relevance to high-income countries and low–middle-income countries. Results In phase 1, 43 interventions were identified, which had low uptake in practice according to 3042 professionals globally. In phase 2, a shortlist of 15 intervention domains was generated. In phase 3, interventions were deemed acceptable for more than 90 per cent of patients except for reducing general anaesthesia (84 per cent) and re-sterilization of ‘single-use’ consumables (86 per cent). In phase 4, the top three shortlisted interventions for high-income countries were: introducing recycling; reducing use of anaesthetic gases; and appropriate clinical waste processing. In phase 4, the top three shortlisted interventions for low–middle-income countries were: introducing reusable surgical devices; reducing use of consumables; and reducing the use of general anaesthesia. Conclusion This is a step toward environmentally sustainable operating environments with actionable interventions applicable to both high– and low–middle–income countries

Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study

Summary Background Congenital anomalies are the fifth leading cause of mortality in children younger than 5 years globally. Many gastrointestinal congenital anomalies are fatal without timely access to neonatal surgical care, but few studies have been done on these conditions in low-income and middle-income countries (LMICs). We compared outcomes of the seven most common gastrointestinal congenital anomalies in low-income, middle-income, and high-income countries globally, and identified factors associated with mortality. Methods We did a multicentre, international prospective cohort study of patients younger than 16 years, presenting to hospital for the first time with oesophageal atresia, congenital diaphragmatic hernia, intestinal atresia, gastroschisis, exomphalos, anorectal malformation, and Hirschsprung’s disease. Recruitment was of consecutive patients for a minimum of 1 month between October, 2018, and April, 2019. We collected data on patient demographics, clinical status, interventions, and outcomes using the REDCap platform. Patients were followed up for 30 days after primary intervention, or 30 days after admission if they did not receive an intervention. The primary outcome was all-cause, in-hospital mortality for all conditions combined and each condition individually, stratified by country income status. We did a complete case analysis. Findings We included 3849 patients with 3975 study conditions (560 with oesophageal atresia, 448 with congenital diaphragmatic hernia, 681 with intestinal atresia, 453 with gastroschisis, 325 with exomphalos, 991 with anorectal malformation, and 517 with Hirschsprung’s disease) from 264 hospitals (89 in high-income countries, 166 in middleincome countries, and nine in low-income countries) in 74 countries. Of the 3849 patients, 2231 (58·0%) were male. Median gestational age at birth was 38 weeks (IQR 36–39) and median bodyweight at presentation was 2·8 kg (2·3–3·3). Mortality among all patients was 37 (39·8%) of 93 in low-income countries, 583 (20·4%) of 2860 in middle-income countries, and 50 (5·6%) of 896 in high-income countries (p<0·0001 between all country income groups). Gastroschisis had the greatest difference in mortality between country income strata (nine [90·0%] of ten in lowincome countries, 97 [31·9%] of 304 in middle-income countries, and two [1·4%] of 139 in high-income countries; p≤0·0001 between all country income groups). Factors significantly associated with higher mortality for all patients combined included country income status (low-income vs high-income countries, risk ratio 2·78 [95% CI 1·88–4·11], p<0·0001; middle-income vs high-income countries, 2·11 [1·59–2·79], p<0·0001), sepsis at presentation (1·20 [1·04–1·40], p=0·016), higher American Society of Anesthesiologists (ASA) score at primary intervention (ASA 4–5 vs ASA 1–2, 1·82 [1·40–2·35], p<0·0001; ASA 3 vs ASA 1–2, 1·58, [1·30–1·92], p<0·0001]), surgical safety checklist not used (1·39 [1·02–1·90], p=0·035), and ventilation or parenteral nutrition unavailable when needed (ventilation 1·96, [1·41–2·71], p=0·0001; parenteral nutrition 1·35, [1·05–1·74], p=0·018). Administration of parenteral nutrition (0·61, [0·47–0·79], p=0·0002) and use of a peripherally inserted central catheter (0·65 [0·50–0·86], p=0·0024) or percutaneous central line (0·69 [0·48–1·00], p=0·049) were associated with lower mortality. Interpretation Unacceptable differences in mortality exist for gastrointestinal congenital anomalies between lowincome, middle-income, and high-income countries. Improving access to quality neonatal surgical care in LMICs will be vital to achieve Sustainable Development Goal 3.2 of ending preventable deaths in neonates and children younger than 5 years by 2030

Soil Electrical Conductivity: An Educational Resource in Experimental Agricultural Research / Condutividade Elétrica do Solo: Um Recurso Educacional em pesquisas Agrárias Experimentais

This article presents a didactic material designed for the teaching of electrical conductivity of a soil sample. This proposal aims to develop targeted content to experiments done in a physics laboratory, produced in form to contemplate the context of students for undergraduate research in the agricultural sciences. This type of initiative is towards the interests of these students to reinforce their learning in areas of professional bond. The results indicated that the experiment has shown fairly consistent in the electrical characterization of the soil, and provide to students a broader view of possibilities of these studies in practical activities

PERFIL DESCRITIVO DE NOTIFICAÇÕES DE TRANSTORNO MENTAL RELACIONADO AO TRABALHO

Este artigo tem como objetivo descrever o perfil sociodemográfico, ocupacional e clínico, relacionado à evolução dos casos e à avaliação da qualidade do preenchimento dos dados de transtornos mentais relacionados ao trabalho notificados em um município do Estado de Minas Gerais, Brasil, entre 2008-2018. O presente estudo descritivo utilizou dados do Sistema Nacional de Agravos Notificados (Sinan). Foram incluídos os 77 casos de transtorno mental notificados no período analisado. Observou-se crescimento de notificações ao longo dos anos, com maior frequência de 2016 a 2018. A maioria dos notificados era do sexo feminino (51,0%), possuía ensino médio completo (53,3%) e foi notificada pelo Centro de Referência em Saúde do Trabalhador (Cerest) (80,5%). As ocupações mais prevalentes entre os casos notificados foram de agente de segurança penitenciário, vigilante, cozinheiro e pedreiro, com predomínio de episódios depressivos. A qualidade do preenchimento foi classificada como boa. Os resultados permitiram a descrição do perfil sociodemográfico, ocupacional e clínico, relacionado à evolução dos casos e à avaliação da qualidade do preenchimento dos dados, evidenciando a importância da articulação intersetorial para promoção de ações de vigilância em saúde mental no trabalho mais efetivas